[Calcimimetic drugs in stage 3-5 chronic kidney disease].
This review is focused on results of application of calcimimetic drug--cinacalcet in the treatment of secondary hyperparathyroidism in patients in 3-5 stage chronic kidney disease (CKD), excluding dialysis patients (stage 5D CKD). Oral administration of cinacalcet (15-180 mg/day) significantly reduced plasma parathormone (PTH) concentrations (> or = 30% as compared to the baseline values), but simultaneously side effects occurred, among them hypocalcemia and hyperphosphatemia. Hypocalcemia was a reason for cinacalcet withdrawal in 2-15% of patients. There is a lack of studies showing the influence of advantages and disadvantages of long-term administration of cinacalcet on outcome of 3-5 stage CKD patients.
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Katedra i Klinika Nefrologii, Transplantologii i Chorób Wewnetrznych. alicja_grzegorzewska@yahoo.com
Alicja E
AE
Grzegorzewska
Leszek
L
Niepolski
D057966:Calcimimetic Agents / Q000627:therapeutic use*; D000069449:Cinacalcet; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000150:complications* / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications*; D009281:Naphthalenes / Q000627:therapeutic use*
D057966:Calcimimetic Agents; D009281:Naphthalenes; D000069449:Cinacalcet